Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera
Marizyme, Inc. (OTCQB:MRZM) has signed a supply and distribution agreement with Abdera Financial, Inc. to distribute its DuraGraft® product in Chile, with potential expansion in South America. This strategic move aims to enhance the market presence and support for DuraGraft, which improves surgical outcomes in coronary artery bypass grafting (CABG) by reducing adverse cardiac events. DuraGraft is already approved in the EU and parts of Asia, but not yet in the U.S. The partnership is expected to strengthen Marizyme’s position in the healthcare market.
- New distribution agreement with Abdera Financial enhances market reach in South America.
- DuraGraft improves CABG surgical outcomes by reducing major adverse events.
- DuraGraft is not yet approved for use in the U.S., limiting market opportunities.
JUPITER, Fla., March 4, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has entered into a supply and distribution agreement with Abdera Financial, Inc., a Chilean based distributor, to distribute Marizyme's DuraGraft® product in Chile, with potential expansion into other countries and regions of the South American market.
Dr. Neil J. Campbell, Marizyme's CEO, President and Board Member, said, "The agreement with Abdera in Chile is both strategic and tactical to set up a market channel, KOL establishment for the South American market and customer support for Marizyme's product line starting with DuraGraft and has the potential to follow on with future platform products."
"We are excited to partner with Marizyme and bring this pivotal product DuraGraft to the Chilean health care market," said Konrad Ziller, Managing Director for Abdera. "DuraGraft will enhance coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction, providing better patient care, and potentially lowering the impact on the overall cost of health care in CABG procedures."
About Abdera, Inc.
Abdera Financial, Inc. is a Chile based distributor with access to the Chilean market to supply and distribute health care and life science products. Abdera has a long and established track record in the successful certification, distribution and marketing of medical and health care products.
About Marizyme, Inc.
Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies that minimize mortality and costs in the acute care space. The Company's flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase® platform. Krillase is not approved for use in the U.S. For more information about Marizyme, visit www.marizyme.com.
Forward-Looking Statements
This press release may contain certain forward-looking statements, including those relating to Marizyme's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable, and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. Forward-looking statements may be identified using forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, including those risks set forth in the Company's risk factor disclosure in the reports that Marizyme files with the Securities and Exchange Commission (SEC File No. 000-53223), uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
CONTACT
Tiberend Strategic Advisors, Inc.
Investors
Miriam Weber Miller
212-375-2694
mmiller@tiberend.com
Media
Ingrid Mezo
646-604-5150
imezo@tiberend.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/marizyme-announces-new-distribution-and-channel-partnership-for-chilean-market-with-abdera-301240433.html
SOURCE Marizyme, Inc.
FAQ
What is Marizyme's recent business development?
What is DuraGraft and its significance?
Where is DuraGraft currently approved?
When was the distribution agreement with Abdera announced?
What potential impact does the agreement have on Marizyme's market?
